Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8N442
UPID:
GUF1_HUMAN
Alternative names:
Elongation factor 4 homolog; GTPase GUF1; Ribosomal back-translocase
Alternative UPACC:
Q8N442; Q5XKM8; Q9H710; Q9H8U4
Background:
Translation factor GUF1, mitochondrial, also known as Elongation factor 4 homolog, GTPase GUF1, and Ribosomal back-translocase, plays a pivotal role in mitochondrial protein synthesis. It ensures the accuracy of protein translation by facilitating a one-codon backward translocation of tRNAs on ribosomes that have translocated improperly, binding to mitochondrial ribosomes in a GTP-dependent manner.
Therapeutic significance:
Linked to Developmental and epileptic encephalopathy 40 (DEE40), a severe early-onset epilepsy with neurodevelopmental impairment, the study of Translation factor GUF1, mitochondrial, offers a promising avenue for therapeutic intervention. Understanding its function could lead to novel strategies for managing DEE40, improving prognosis and quality of life for affected individuals.